NanoCell Announces Publication of Research Data in Journal for ImmunoTherapy of Cancer Demonstrating First-in-Class Non-Viral DNA-Based In Vivo CAR-T Generation
NanoCell Therapeutics, Inc. (“NanoCell”), a biotechnology company developing a non-viral, DNA-based in vivo gene therapy platform, today announced the publication of research data in the Journal for ImmunoTherapy of Cancer demonstrating its novel targeted lipid nanoparticle delivery system, termed NCtx. This technology enables the direct in vivo generation of chimeric antigen receptor T-cells (CAR-T), potentially transforming the accessibility and scalability of CAR-T therapies for cancer patients worldwide.
